Shares of PureTech Health plc (LON:PRTC – Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as GBX 134.80 ($1.68) and last traded at GBX 136.40 ($1.70), with a volume of 325557 shares changing hands. The stock had previously closed at GBX 138 ($1.72).
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 455 ($5.68) price objective on shares of PureTech Health in a research note on Monday, December 16th.
Read Our Latest Stock Report on PRTC
PureTech Health Stock Performance
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Read More
- Five stocks we like better than PureTech Health
- Options Trading – Understanding Strike Price
- Bloom Energy: Powering the Future With Decentralized Energy
- What is the Shanghai Stock Exchange Composite Index?
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- What is the Hang Seng index?
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.